Drug Developed for Inherited Bleeding Disorder Shows Promising Trial Results
A study led by Mass General Brigham researchers found that engasertib lessened bleeding events for patients with HHT, the second most common inherited bleeding disorder.
Press Release5 Minute ReadAug | 16 | 2021
Jagpreet Chhatwal, PhDThese projections should serve as a warning sign, especially in states that could have higher daily COVID-19 deaths than their previous peaks.
BOSTON – Investigators who previously developed the COVID-19 Simulator (www.covid19sim.org)—which models the trajectory of COVID-19 in the U.S. at the state and national levels—have applied the tool to analyze potential scenarios in which the COVID-19 Delta variant becomes dominant in every state. The analysis, which is published on the preprint server medRxiv, reveals that the combination of high transmissibility of the Delta variant, low vaccination coverage in several regions, and more relaxed attitudes toward social distancing will likely lead to a surge in COVID-19–related deaths in at least 40 states.
The simulator also predicts that in several states, daily COVID-19–related deaths could exceed the peak daily deaths that occurred in early 2021 if current social distancing behaviors and vaccination rates remain unchanged.
An additional 157,000 COVID-19–related deaths could occur across the United States between August 1 and December 31, 2021. The model projects approximately 20,700 COVID-19–related deaths in Texas, 16,000 in California, 12,400 in Florida, 12,000 in North Carolina, and 9,300 in Georgia during this period. In contrast, the projected number of COVID-19–related deaths would remain below 200 in New Jersey, Massachusetts, Connecticut, Vermont and Rhode Island.
The team’s projections are updated weekly by incorporating vaccination rates and social distancing measures in each state, and the latest results can be found at the COVID-19 Simulator website.
“These projections should serve as a warning sign, especially in states that could have higher daily COVID-19 deaths than their previous peaks,” says lead author Jagpreet Chhatwal, PhD, associate director of Massachusetts General Hospital’s Institute for Technology Assessment and an assistant professor at Harvard Medical School. “We also hope that our projections can help policymakers bring back mask mandates and further advocate for COVID-19 vaccines.”
Senior author Benjamin P. Linas, MD, MPH, a professor of medicine at Boston University School of Medicine, adds that although it was hoped that the pandemic was waning, additional action is needed. “If you are not vaccinated, you are at high risk because of the Delta variant. August 2021 is potentially more dangerous to you than August 2020,” he says. “If you are vaccinated, you are much safer, but you should still care about this ongoing transmission because it creates the circumstances that generate new variants. If we want to end this pandemic, then all Americans need to be vaccinated and at least right now, we should be masking when in public indoor spaces.”
Co-author Jade Yingying Xiao, a PhD student at Georgia Tech, notes that if recent estimates of the reproduction number of the Delta variant are correct, then the team’s model implies current levels of social distancing are reducing transmission by 30% to 40%. “We can easily foresee this number dropping as we move ahead into the fall months with schools and colleges reopening,” she says.
Co-authors include Peter Mueller, Turgay Ayer, Madeline Adee, Ozden O. Dalgic and Mary Ann Ladd.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."
A study led by Mass General Brigham researchers found that engasertib lessened bleeding events for patients with HHT, the second most common inherited bleeding disorder.
The Sean M. Healey & AMG Center for ALS at Mass General Brigham has selected Tiziana Life Sciences as one of the companies to enter the Healey ALS MyMatch Program. Learn more.
Mass General Brigham study of more than 11,000 adolescents and young adults found those who took buprenorphine for 12 months had almost half the risk of overdose compared to those who discontinued early.
In a study of nearly 30,000 female nurses under age 50, Mass General Brigham researchers found that a high intake of ultra-processed foods was associated with increased risk of adenomas, colon polyps which can be precursors of colorectal cancer.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital has contracted with Inflammasome Therapeutics to design a new Healey ALS MyMatch trial. Learn more.
Children born to mothers who had COVID-19 while pregnant face an elevated risk of developmental disorders by the time they turn 3 years old, including speech delays, autism, motor disorders, and other developmental delays, according to new research by investigators at Mass General Brigham.
